A statement released earlier today by B. Riley about Mazor Robotics Ltd – ADR (NASDAQ:MZOR) ups the target price to $25.00
- Updated: October 6, 2016
In a report released on Thursday October 06, 2016 B. Riley increased the stock price target of Mazor Robotics Ltd – ADR (NASDAQ:MZOR) to $25.00 reporting a potential upside of 0.10%.
Having a price of $22.71, Mazor Robotics Ltd – ADR (NASDAQ:MZOR) traded -3.93% lower on the day. The last stock close price is up 27.35% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Mazor Robotics Ltd – ADR has recorded a 50-day average of $23.23 and a two hundred day average of $17.83. Volume of trade was up over the average, with 372,079 shares of MZOR changing hands over the typical 152,182
With a total market value of $0, Mazor Robotics Ltd – ADR has with a one year low of $8.31 and a 52 week high of $26.48 .
In addition to B. Riley reporting its stock price target, a total of 5 brokers have issued a research note on the stock. The consensus target price is $17.10 with 2 firms rating the stock a strong buy, 2 firms rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Mazor Robotics Ltd – ADR (NASDAQ:MZOR)
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.